上海科棋药业科技

Keqi Bio is a clinical-stage biotechnology company headquartered in Shanghai, China, dedicated to the development of innovative chimeric antigen receptor T-cell (CAR-T) therapies. The company's primary focus is on overcoming the barriers to treating solid tumors, particularly liver and gastrointestinal cancers. Its lead candidate, KQ-CH2-1, is a GPC3-targeted CAR-T therapy currently undergoing clinical evaluation for hepatocellular carcinoma. Keqi Bio leverages proprietary technology to improve the infiltration and survival of T-cells within the immunosuppressive tumor microenvironment. By integrating advanced genetic engineering with clinical insights, the company aims to deliver potent and durable treatments for patients with refractory malignancies. Keqi Bio has attracted significant investment from prominent venture capital firms to accelerate its pipeline development.